BPC May 19 updates – PTIE DRRX Advisory Committee Meeting set for August 5 + updates for AGIO ASND GBT IMMU INFI ONCE QURE STML TENX TNXP

May 19, 2016 No Comments by

Updates to the Company Pipeline Database for May 19, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AGIO 45.30 AG-348 Pyruvate kinase deficiency Phase 2 Phase 2 first data due at European Hematology Association (EHA) in June 11 2016 ASND 14.03 TransCon Growth hormone deficiency in children Phase 2 Phase […]

Daily News Read more

ORMP Phase 2b diabetes data due in around two weeks + updates from reporting companies ARQL ESPR EXEL INFI LOXO MGNX NVAX ONCE OPHT VNDA XOMA

May 05, 2016 No Comments by

Updates to the Company Pipeline Database for May 4, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ORMP 9.50 ORMD-0801 Type 2 Diabetes Phase 2 Phase 2 top-line data due around May 18 2016 – noted on May 4 that data will be released in around 2 weeks ESPR […]

Daily News Read more

PTCT receives Refusal to File Letter. CLDX Phase 3 data due March + updates for ALDR AMAG ARIA BCRX ICPT INFI NVIV PRTK PTCT

Feb 24, 2016 No Comments by

Updates to the Company Pipeline Database for February 23, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALDR 19.29 ALD403 Chronic Migraine Phase 2b Phase 2b data due 1Q 2016 ALDR 19.29 ALD403 – PROMISE 1 Frequent episodic migraine Phase 3 Phase 3 topline data due 1H 2017 AMAG […]

Daily News Read more

65 pipeline updates predominantly from companies attending the JP Morgan Healthcare Conference

Jan 12, 2016 No Comments

Pipeline updates galore as companies give latest guidance at the JP Morgan Healthcare Conference. Click HERE to register for meeting information and webcasts. Latest updates to the Company Pipeline Database from January 11, 2016. Refer to the FDA Calendar for upcoming catalysts: ACOR 39.98 Dalfampridine Post stroke deficits Phase 2b/3 Phase 3 interim data due 2016 ACOR 39.98 CVT-301 […]

Read more

Pipeline updates for ADHD ALXA ANAC ARQL CCXI CERU CLVS CTIC GWPH INFI MGNX PGNX PTLA RDUS SCMP TRLPF TTPH VNDA VSAR XNPT

May 07, 2015 No Comments

Latest updates to the Company Pipeline Database for May 6 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ADHD 5.53 MDX (Metadoxine Extended Release (MG01CI)) Fragile X Syndrome Phase 2b Phase 2b enrolment due to be completed 1Q 2015. Data due 2Q 2015 ADHD 5.53 MDX (Metadoxine Extended Release (MG01CI)) Adult […]

Read more

Pipeline updates for ALKS ARDX ATRS BMRN CEMP CLDX CLVS DPRX DYAX EXEL FLXN INFI NKTR TBPH XOMA

Feb 26, 2015 No Comments

Latest updates to the Company Pipeline Database for February 24-25, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ALKS 71.11 ALKS 5461 Major depressive disorder Phase 2 Phase 3 (two trials) initiated Jun 2014. Data due 2016. Third Phase 3 trial initiated mid 2014. Data due […]

Read more

Latest pipeline updates. 40 in total!

Jan 13, 2015 No Comments

Latest updates to the Company Pipeline Database from January 12 and 13, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated ATRS 2.46 VIBEX QuickShot Testosterone deficiency Phase 3 Phase 3 initiated July 2014. Final patient dosed Nov 2015. Top-line pharmacokinetic data due 2Q 2015 1/14/2015 CPRX 2.87 […]

Read more

NBIX meets Phase 3 endpoint + updates for ALNY CNAT CYTR PLX GALE GWPH INFI IXPL KMDA LGND OTIC RGLS SGYP VSAR VSTM

Jan 09, 2015 No Comments

Latest updates to the Company Pipeline Database from January 8, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated ALNY 101.70 Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 Phase 3 trial initiated Nov 2013, continues to enrol patients as of Nov 2014. Expects […]

Read more

Updates for GALE SCMP BLRX APPA RPTP ACOR RLYP INFI HALO ARNA CLVS SGEN ICPT GILD CUR MRK CYCC CRIS ACHN

Jan 13, 2014 No Comments

Curis, Inc.(NASDAQ:CRIS) provided an update noting that Phase 2 data of everolimus for Operable Nodular BCC (basal cell carcinoma) are due 1Q 2014. Their submission to the FDA regarding the partial clinical hold of CUDC-427 is due shortly. A Phase 2 trial of Debio 0932 is due to be to initiated in 2H 2014. Galena Biopharma (Nasdaq:GALE) announced it has […]

Read more

CNDO Phase 2 trial halted. MACK data release delay. ARQL data due 1Q 2014 + pipeline updates for AVEO APPY INSV NKTR APPY CCXI BCRX OXXI ANAC AMBI TSRO INFI + SLXP SNTS TTPH news

Nov 08, 2013 No Comments

Coronado Biosciences, Inc. (NASDAQ: CNDO $1.63) announced that the Independent Data Monitoring Committee (IDMC) recommended that their Phase 2 clinical trial in Europe evaluating Trichuris suis ova (TSO) in Crohn’s disease be stopped due to lack of efficacy. AVEO Oncology (NASDAQ: AVEO $2.07) provided an update noting that data are anticipated in 2014 from the Phase 2 trial […]

Read more

NKTR misses Phase 2 endpoint. DRTX files NDA + updates for SNSS SRPT INFI EXEL ACOR AMAG NYMX

Sep 26, 2013 No Comments

Nektar Therapeutics (Nasdaq: NKTR $10.44) announced that it failed to meet the primary endpoint in its Phase 2 trial of NKTR-181 for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis of the knee. The company noted that the placebo did not show the expected increase in pain scores as expected. Durata Therapeutics, Inc. (Nasdaq:DRTX […]

Read more